Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients-Reference-Cited by-同舟云学术

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients

Published:2017-11-28 Issue:1 Volume:19 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Helland Thomas,Henne Nina,Bifulco Ersilia,Naume Bjørn,Borgen Elin,Kristensen Vessela N.,Kvaløy Jan T.,Lash Timothy L.,Alnæs Grethe I. G.,van Schaik Ron H.,Janssen Emiel A. M.,Hustad Steinar,Lien Ernst A.,Mellgren Gunnar,Søiland Håvard

Funder

Helse Vest

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-017-0916-4.pdf

Reference36 articles.

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

2. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97(22):1652–62.

3. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816.

4. Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Mobus V, Scheithauer H, et al. 14th St. Gallen International Breast Cancer Conference 2015: evidence, controversies, consensus—primary therapy of early breast cancer: opinions expressed by German experts. Breast Care (Basel, Switzerland). 2015;10(3):211–9.

5. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H-J, Panel Members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients;Clinical Pharmacology & Therapeutics;2024-07-22

2. A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients;Clinical Pharmacology & Therapeutics;2024-03-19

3. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort;Clinical Pharmacology & Therapeutics;2024-03-18

4. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?;Drugs;2024-03-14

5. Impact of CYP2D6, CYP2C9/19, CYP3A4, UGT, and SULT Variability on Tamoxifen Metabolism in Breast Cancer Treatment;Journal of Current Oncology;2024-02-27